Koninklijke Philips N.V. stock (NL0000009538): ex-dividend date set for May 12

Koninklijke Philips N.V. (PHG) goes ex-dividend on May 12, 2026, with shareholders of record on May 13 eligible for the payout. The healthcare technology firm recently unveiled its Titanion MR system.

Koninklijke Philips N.V. will trade ex-dividend on May 12, 2026, meaning shareholders of record as of May 13, 2026, will receive the upcoming dividend payment, according to Futunn as of May 10, 2026. This event comes amid recent product innovation, including the launch of the Titanion MR, an ultra-high-gradient 3.0T MRI system aimed at advancing quantitative biomarker imaging. The stock closed at $28.88 on NYSE on October 24, 2025, per MarketBeat as of 10/24/2025.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Koninklijke Philips N.V.
• Sector/industry: Healthcare technology
• Headquarters/country: Netherlands
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Diagnosis & treatment, connected care, personal health
• Home exchange/listing venue: Euronext Amsterdam (PHIA); NYSE ADR (PHG)
• Trading currency: EUR (primary); USD (ADR)

Koninklijke Philips N.V.: core business model

Koninklijke Philips N.V. develops and manufactures medical systems, consumer electronics, lighting, and associated software and services. The company operates through three main segments: Diagnosis & Treatment, Connected Care, and Personal Health. Diagnosis & Treatment focuses on image-guided therapy, ultrasound, and magnetic resonance imaging equipment. Connected Care provides patient monitoring, cardiology informatics, and enterprise diagnostic informatics solutions. Personal Health includes oral healthcare, mother & child care, and pain relief products. Philips generates annual revenue of around $19.50 billion as reported in recent filings, with 66,678 employees worldwide.

The firm's business model emphasizes innovation in healthcare technology, serving hospitals, clinics, and consumers globally. It holds a dividend yield of 2.85% compared to the medical products industry average of 1.88%, according to MarketBeat data as of 10/24/2025. Philips lists primarily on Euronext Amsterdam under ticker PHIA, with ADRs trading on NYSE as PHG, offering US investors direct exposure to European healthcare tech.

Main revenue and product drivers for Koninklijke Philips N.V.

Diagnosis & Treatment remains the largest revenue contributor, driven by advanced imaging systems like MRI and CT scanners. Recent innovation includes the Titanion MR, unveiled in 2026, which expands ultra-high-gradient MRI capabilities toward whole-body quantitative biomarkers, as announced on the company website. Connected Care benefits from demand for remote monitoring amid rising chronic disease prevalence. Personal Health taps into consumer trends for at-home health devices. In Q3 2025 comparable sales grew 1% with 3% growth in North America, per company reports.

Key products include Ingenia MRI systems and Azurion image-guided therapy platforms. Philips reported net income challenges with -$758.55 million in the latest period versus industry peers, but maintains a market cap of $27.76 billion. US investors note Philips' significant exposure to the American healthcare market, where it derives substantial revenue from hospital equipment sales.

Industry trends and competitive position

The medical devices sector sees growth from aging populations and precision medicine. Philips competes with firms like Medtronic and GE HealthCare, holding a price/book ratio of 1.96 versus the industry's 3.47, per MarketBeat. Its focus on AI-integrated diagnostics positions it well in a market projected to expand, with Philips' 7-day performance at 1.19% outperforming peers' 0.74% as of late 2025 data.

Why Koninklijke Philips N.V. matters for US investors

Philips' NYSE-listed ADRs (PHG) provide US retail investors easy access to a diversified healthcare tech leader with strong North American revenue. The company's innovations like Titanion MR align with US trends in advanced imaging, while its dividend offers yield attractive to income-focused portfolios amid volatile markets.

Conclusion

Koninklijke Philips N.V. approaches its ex-dividend date on May 12, 2026, highlighting its commitment to shareholder returns with a competitive yield. Recent product launches like Titanion MR underscore ongoing innovation in healthcare tech. While facing profitability pressures, the company's global footprint and US market exposure continue to draw investor interest. Market dynamics and peer comparisons suggest monitoring upcoming earnings for further insights.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.